TDMS Study 05031-02 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
MERCURIC CHLORIDE
NTP Experiment-Test: 05031-02 Report: PEIRPT05
Study Type: CHRONIC Date: 09/04/94
Route: GAVAGE Time: 17:35:59
Facility: International Research and Development Corp.
Chemical CAS #: 7487-94-7
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 2.5MG/KG 5.0MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60
Scheduled Sacrifice 10 10 10
Early Deaths
Moribund 14 14 9
Dead 1 7 11
Survivors
Terminal Sacrifice 35 27 29
Moribund 1 1
Wrong Sex 1
Animals Examined Microscopically 50 49 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (50) (49) (50)
Intestine Large, Rectum (50) (46) (50)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
Liver (50) (49) (50)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
Neoplastic Nodule 1 (2%)
Schwannoma Malignant, Metastatic, Uncertain
Primary Site 1 (2%)
Mesentery (2) (2) (2)
Pancreas (50) (49) (50)
Salivary Glands (50) (49) (50)
Stomach, Forestomach (50) (49) (50)
Squamous Cell Papilloma 2 (4%)
Stomach, Glandular (50) (49) (50)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (49) (50)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
Schwannoma Malignant, Metastatic, Uncertain
Primary Site 1 (2%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 2.5MG/KG 5.0MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (49) (49) (50)
Adenoma 1 (2%) 1 (2%)
Adrenal Gland, Medulla (48) (49) (49)
Pheochromocytoma Benign 2 (4%) 1 (2%) 2 (4%)
Bilateral, Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (50) (49) (50)
Adenoma 1 (2%) 2 (4%)
Pituitary Gland (50) (49) (50)
Pars Distalis, Adenoma 21 (42%) 20 (41%) 19 (38%)
Pars Distalis, Carcinoma 1 (2%)
Thyroid Gland (50) (48) (49)
C-Cell, Adenoma 3 (6%) 3 (6%) 1 (2%)
C-Cell, Carcinoma 1 (2%) 2 (4%) 1 (2%)
Follicular Cell, Adenoma 2 (4%)
Follicular Cell, Carcinoma 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (46) (46) (45)
Adenoma 1 (2%) 2 (4%) 3 (7%)
Carcinoma 1 (2%) 1 (2%) 3 (7%)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
Ovary (50) (49) (50)
Arrhenoblastoma NOS 1 (2%)
Granulosa Cell Tumor Benign 1 (2%)
Luteoma 1 (2%)
Uterus (50) (49) (50)
Leiomyoma 1 (2%)
Leiomyosarcoma 1 (2%) 1 (2%)
Polyp Stromal 1 (2%)
Endometrium, Polyp Stromal 8 (16%) 11 (22%) 9 (18%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (49) (50)
Lymph Node (44) (48) (49)
Mediastinal, Follicular, Carcinoma,
Metastatic, Thyroid Gland 1 (2%)
Page 3
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 2.5MG/KG 5.0MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Lymph Node, Mesenteric (40) (28) (47)
Spleen (50) (49) (50)
Capsule, Fibrous Histiocytoma, Metastatic,
Uncertain Primary Site 1 (2%)
Thymus (48) (43) (48)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (48) (50)
Adenocarcinoma 3 (6%) 2 (4%)
Adenoma 1 (2%)
Fibroadenoma 15 (30%) 5 (10%) 2 (4%)
Skin (50) (49) (50)
Fibrosarcoma 2 (4%)
Keratoacanthoma 2 (4%)
Lip, Squamous Cell Carcinoma 1 (2%)
Sebaceous Gland, Adenoma 1 (2%)
Subcutaneous Tissue, Fibroma 1 (2%) 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (49) (50)
Astrocytoma NOS 1 (2%)
Ependymoma Benign 1 (2%)
Glioma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (49) (50)
Histiocytic Sarcoma 1 (2%)
Nose (49) (49) (50)
Trachea (50) (49) (50)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 2.5MG/KG 5.0MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (49) (50)
Histiocytic Sarcoma 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Urinary Bladder (50) (48) (50)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(49) *(50)
Histiocytic Sarcoma 1 (2%)
Leukemia Monocytic 1 (2%)
Leukemia Mononuclear 20 (40%) 11 (22%) 13 (26%)
Mesothelioma Benign 1 (2%)
Mesothelioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 2.5MG/KG 5.0MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 46 42 39
Total Primary Neoplasms 82 76 67
Total Animals with Benign Neoplasms 35 37 31
Total Benign Neoplasms 54 55 44
Total Animals with Malignant Neoplasms 24 15 21
Total Malignant Neoplasms 28 19 23
Total Animals with Metastatic Neoplasms 1 1 1
Total Metastatic Neoplasm 1 2 7
Total Animals with Malignant Neoplasms 1 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 2
Total Uncertain Neoplasms 2
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 2.5MG/KG 5 MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60
Scheduled Sacrifice 10 10 10
Early Deaths
Moribund 20 19 32
Dead 4 21 13
Survivors
Terminal Sacrifice 26 10 5
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (50) (50) (50)
Intestine Small, Duodenum (50) (49) (50)
Intestine Small, Ileum (49) (50) (49)
Intestine Small, Jejunum (49) (50) (50)
Carcinoma 2 (4%)
Liver (50) (50) (50)
Hemangioma 1 (2%)
Hepatocellular Carcinoma 1 (2%)
Neoplastic Nodule 1 (2%) 1 (2%)
Osteosarcoma, Metastatic, Nose 1 (2%)
Sarcoma, Metastatic 1 (2%)
Mesentery (2) (10) (6)
Pancreas (50) (50) (50)
Adenoma 1 (2%)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
Stomach, Forestomach (49) (50) (50)
Squamous Cell Papilloma 2 (4%) 6 (12%)
Squamous Cell Papilloma, Multiple 1 (2%) 6 (12%)
Stomach, Glandular (50) (50) (50)
Tongue (1)
Squamous Cell Papilloma 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 2.5MG/KG 5 MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (50) (50)
Adenoma 2 (4%)
Carcinoma 1 (2%) 1 (2%)
Extra Adrenal Tissue, Adenoma 1 (2%)
Adrenal Gland, Medulla (48) (50) (49)
Pheochromocytoma Malignant 2 (4%) 1 (2%)
Pheochromocytoma Complex 1 (2%)
Pheochromocytoma Benign 16 (33%) 11 (22%) 20 (41%)
Bilateral, Pheochromocytoma Malignant 1 (2%)
Bilateral, Pheochromocytoma Benign 5 (10%) 7 (14%) 3 (6%)
Islets, Pancreatic (50) (50) (50)
Adenoma 3 (6%)
Parathyroid Gland (49) (44) (49)
Adenoma 1 (2%)
Pituitary Gland (50) (49) (50)
Pars Distalis, Adenoma 14 (28%) 4 (8%) 4 (8%)
Pars Distalis, Carcinoma 1 (2%)
Pars Nervosa, Adenoma 1 (2%)
Thyroid Gland (50) (50) (50)
C-Cell, Adenoma 5 (10%) 3 (6%) 1 (2%)
C-Cell, Carcinoma 2 (4%)
Follicular Cell, Adenoma 1 (2%) 4 (8%)
Follicular Cell, Carcinoma 1 (2%) 2 (4%) 6 (12%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (1)
Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (49) (50)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
Preputial Gland (49) (46) (48)
Adenoma 3 (6%) 2 (4%) 2 (4%)
Basal Cell Adenoma 1 (2%)
Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Prostate (49) (50) (50)
Seminal Vesicle (3) (1)
Testes (50) (49) (50)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
Page 8
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 2.5MG/KG 5 MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Bilateral, Interstitial Cell, Adenoma 39 (78%) 28 (57%) 24 (48%)
Interstitial Cell, Adenoma 6 (12%) 9 (18%) 15 (30%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (49) (50)
Lymph Node (49) (48) (49)
Mandibular, Osteosarcoma, Metastatic, Nose 1 (2%)
Mediastinal, Fibrous Histiocytoma,
Metastatic, Uncertain Primary Site 1 (2%)
Mediastinal, Hemangiosarcoma 1 (2%)
Lymph Node, Mesenteric (42) (42) (44)
Fibrous Histiocytoma, Metastatic, Uncertain
Primary Site 1 (2%)
Spleen (50) (50) (50)
Sarcoma, Metastatic 1 (2%)
Capsule, Fibrous Histiocytoma, Metastatic,
Uncertain Primary Site 1 (2%)
Thymus (46) (46) (45)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (47) (50) (45)
Fibroadenoma 2 (4%) 1 (2%)
Skin (50) (50) (50)
Keratoacanthoma 5 (10%) 1 (2%)
Trichoepithelioma 1 (2%) 1 (2%)
Face, Papilloma 1 (2%)
Subcutaneous Tissue, Fibroma 3 (6%) 1 (2%) 3 (6%)
Tail, Neurofibroma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50)
Astrocytoma NOS 2 (4%)
Glioma Benign 1 (2%)
Oligodendroglioma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 2.5MG/KG 5 MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50)
Alveolar/Bronchiolar Adenoma 1 (2%)
Carcinoma, Metastatic, Adrenal Gland 1 (2%)
Sarcoma, Metastatic 1 (2%)
Alveolar Epithelium, Carcinoma 1 (2%)
Nose (50) (47) (50)
Osteosarcoma 1 (2%)
Mucosa, Polyp 1 (2%)
Trachea (50) (50) (50)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Zymbal's Gland (1)
Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50)
Lipoma 1 (2%)
Liposarcoma 1 (2%)
Sarcoma 1 (2%)
Renal Tubule, Adenoma 2 (4%)
Urinary Bladder (50) (50) (50)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Leukemia Mononuclear 28 (56%) 12 (24%) 14 (28%)
Mesothelioma Benign 1 (2%)
Mesothelioma Malignant 1 (2%) 1 (2%)
Mesothelioma NOS 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 2.5MG/KG 5 MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 49 42 45
Total Primary Neoplasms 151 101 121
Total Animals with Benign Neoplasms 48 41 44
Total Benign Neoplasms 109 84 91
Total Animals with Malignant Neoplasms 34 16 23
Total Malignant Neoplasms 42 16 28
Total Animals with Metastatic Neoplasms 2 2
Total Metastatic Neoplasm 8 4
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1 2
Total Uncertain Neoplasms 1 2
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------